SentimentTrading

Viking Therapeutics Q1 2026: Strong Cash, R&D Push, and Dual Agonist Pipeline Progress

Viking Therapeutics Q1 2026: $603M cash, robust pipeline with phase‑3 dual‑agonist VK2735, and new amylin drug, poised to reshape obesity treatment while managing R&D losses.

30/04/2026, 12:18

3 minutes to read

Market Overview

Top Sector News (Financial Services )

Sinolink Securities to Report Q1 2025 Earnings Amid Market Volatility and Strategic Shifts

27/04/2025

FlatexDEGIRO AG Announces Leadership Changes and Strategic Realignment Ahead of AGM

25/04/2025

SoFi Technologies: Navigating Volatility with Growth Potential in Fintech

26/04/2025

St. James's Place PLC: A Pillar of Stability and Growth in Global Wealth Management

28/04/2025

Viking Therapeutics Q1 2026: Strong Cash, R&D Push, and Dual Agonist Pipeline Progress

Top News

Perfect World Rides China's Gaming Boom with 2026 "Yihuan" Launch

Worldline Strengthens Core, Appoints New Risk Officer, & Raises €500 M Capital

Hengtong Optic‑Electric Surges as G.652.D Fiber Prices Reach 7‑Year High

SMT Scharf AG's 15% Stake Shift: Strategic Voting Rights Spark Governance Change